John M. Capek - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: EXECUTIVE VICE PRESIDENT
Issuer ticker: ABT
Reported as of: 17 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Feb 2023, 17:43:25 UTC
Prior SEC filing: 02 Mar 2022
Next SEC filing: 02 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ John M. Capek by Jessica H. Paik, Attorney-in-Fact

Key filing fact

John M. Capek filed Form 4 for ABBOTT LABORATORIES (ABT) on 22 Feb 2023.

Key facts

This page summarizes John M. Capek's Form 4 filing for ABBOTT LABORATORIES (ABT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Feb 2023, 17:43.

Change

Previous filing in this sequence was filed on 02 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value: $0
Shares: +15,855
Change %: +4.8%
Price: $0.000000
Shares after: 345,690
Date: 17 Feb 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +62,527
Change %
Price: $0.000000
Shares after: 62,527
Date: 17 Feb 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 62,527
Exercise price: $106.24
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

Footnote F2

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,842 on February 17, 2024, 20,842 on February 17, 2025, and 20,843 on February 17, 2026.